Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

17.30 +0.37 (+2.19%)
Streaming Delayed Price Updated: 12:07 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Analyst Expectations for ACADIA Pharmaceuticals's Future
Via Benzinga
Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development
From Acadia Pharmaceuticals Inc.
Via Business Wire
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics
From Acadia Pharmaceuticals Inc.
Via Business Wire
Mizuho Maintains Neutral Rating for ACADIA Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACADIA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD
From Kahn Swick & Foti, LLC
Via Business Wire
Acadia Trofinetide Phase III Clinical Top-Line Results Positive
Via AB Newswire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
Upgrades 
Via Benzinga
Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results
From Acadia Pharmaceuticals Inc.
Via Business Wire
ACADIA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD
From Kahn Swick & Foti, LLC
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed
From Acadia Pharmaceuticals
Via Business Wire
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
Via Benzinga
U.S. FDA Accepts Acadia's Filing For Rett Syndrome Candidate Under Priority Review
The U.S. Food and Drug Administration (FDA) has accepted for filing Acadia Pharmaceuticals’ (NASDAQ: ACAD) New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome. The regulatory... 
Via Benzinga
Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
ACADIA Pharmaceuticals's Return On Capital Employed Insights
According to Benzinga Pro data, during Q2, ACADIA Pharmaceuticals (NASDAQ:ACAD) posted sales of $134.56 million. Earnings were up 69.92%, but ACADIA Pharmaceuticals still reported an overall loss of... 
Via Benzinga
Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data
Via Benzinga
ACADIA Pharmaceuticals Faces Several Price Target Cuts After Q2 Results, But This Analyst Disagrees
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported upbeat results for its second quarter after the closing bell on Monday. 
Via Benzinga
NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday
Raymond James cut the price target on NVIDIA Corporation (NASDAQ: NVDA) from $250 to $240. Raymond James analyst Melissa Fairbanks maintained the stock with a Strong Buy. NVIDIA shares fell 2.8% to... 
Via Benzinga
ACADIA Pharmaceuticals: Q2 Earnings Insights
  ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q2 earnings results on Monday, August 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results
From Acadia Pharmaceuticals Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
  
Via Benzinga
8 Analysts Have This to Say About ACADIA Pharmaceuticals
Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.